DUBLIN–(BUSINESS WIRE)–The “Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, Scale of Operation, Type of Drug Molecule, Type of Continuous Manufacturing Related Service Offered, Type of Dosage Form Offered, Installed Capacity and Geographical Regions, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
This report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
Over time, advances in manufacturing technologies have prompted pharmaceutical companies to shift from the traditional multi-step, batch manufacturing processes to faster and relatively efficient continuous manufacturing. Continuous manufacturing, also known as continuous flow chemistry, is an advanced manufacturing technology, which drives operations in a continuous manner (247) in one facility, without hold times.
The concept was first described in the 1700s, for the production of pig iron in blast furnaces. Since then, the technique has been adopted by various industries, including automotive, food and beverage, oil refining, chemicals, pulp and paper, electronics, metal smelting, steel making, and waste-water treatment industries. In recent years, continuous manufacturing has gained traction in the biopharmaceutical industry as well, having captured the attention of big pharma players, as well as leading contract manufacturing organizations (CMOs).
Moreover, the ongoing COVID-19 pandemic has prompted the pharmaceutical industry to shift to continuous manufacturing to scale up processing. The continuous manufacturing technology offers several benefits, including reduction in manufacturing cost (by 15-30%), manpower (by 50-70%) and power consumption (by 40%), lesser product deviation (by 50%), smaller footprint (by 50-70%) and faster scale up. Specifically, for biologics, continuous manufacturing, through upstream perfusion, is already a well-established method.
In fact, more than 20 biologics manufactured using this approach have been approved by the FDA. Moreover, continuous processing technology presents a versatile and beneficial manufacturing approach for oral solid dosage (OSD) forms and small molecules as well. In the last few years, many orally administrable drugs, including TRIKAFTA (Vertex Pharmaceuticals, 2019), DAURISMOT (Pfizer, 2018), SYMDEKO (Vertex Pharmaceuticals, 2018), VERZENIO (Eli Lilly, 2017), PREZISTA (Johnson & Johnson, 2016) and ORKAMBI (Vertex Pharmaceuticals, 2015) manufactured using the continuous technique, have been approved by the FDA.
Presently, several technology providers / equipment suppliers are engaged in offering the necessary technologies and equipment for continuous manufacturing; these include continuous flow reactors (plug flow reactors, continuous stirred tank reactors (CSTR) and microreactors), continuous granulators, continuous coaters, continuous mixers / blenders, continuous chromatography equipment, continuous dryers and process analytical technologies (PAT).
Key Questions Answered
- Who are the leading players providing in the continuous manufacturing services?
- In which regions are the majority of continuous manufacturers located?
- What is the installed, global capacity for continuous manufacturing?
- Which partnership models are commonly adopted by stakeholders engaged in providing continuous manufacturing services?
- Who are the other key stakeholders (modular facility providers and technology / equipment developers) in this domain?
- Which factors are likely to influence the evolution of this market?
- How has the patent landscape evolved over the last several years?
- Which research institutes have received relatively more grants for projects related to continuous manufacturing?
- Which organizations have taken significant in-house initiatives in the field of continuous manufacturing?
- How is the current and future market opportunity likely to be distributed across key market segments?
Companies Mentioned
- AbbVie
- AC Immune
- ACG
- Ajinomoto OmniChem
- Almac
- Amar Chemistry
- Amgen
- AMPAC Fine chemicals
- AMRI
- Angelini Pharma
- Arcinova
- AstraZeneca
- Asymchem
- Aurobindo Pharma
- BASF Pharma
- Bayer
- Bellen Chemistry
- Biosana Pharma
- BioXcellence (Contract Manufacturing unit of Boehringer Ingelheim)
- Boehringer Ingelheim
- Bristol Myers Squibb
- Cambrex
- Cell Culture Company
- Cerbios-Pharma
- Cipla
- Colorcon
- Consort Medical
- Continuus Pharmaceuticals
- Corden Pharma
- Dalton Pharma Services
- Dottikon Exclusive Synthesis
- DSM Pharmaceutical
- Eburon Organics
- Eli Lilly
- Enzene Biosciences
- Esco Aster
- Evonik
- Farmhispania
- FUJIFILM Diosynth Biotechnologies
- GEA
- Glatt Group
- Goodwin Biotechnology
- Grace
- GSK
- Hanmi Pharmaceuticals
- Hovione
- InnoSyn
- Johnson & Johnson
- Johnson Matthey
- Kaneka
- Lonza
- Medichem
- Merck
- NJ Bio
- Novartis
- Onyx Scientific
- Patheon (Thermo fisher scientific)
- Pfizer
- PharmaBlock Sciences
- Phlow
- Procos
- Promega
- Sanofi
- Servier
- Siegfried
- SK Pharmteco
- STA Pharmaceuticals (a subsidiary of WuXi AppTec)
- Sterling Pharma
- Syntegon Technology
- Vertex Pharmaceuticals
- WuXi Biologics
For more information about this report visit https://www.researchandmarkets.com/r/kbjsgi
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900